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Over the last few years, recent advances in antiplatelet and
anticoagulant therapies have significantly altered the man-
agement strategies and outcomes of patients presenting with
unstable angina (UA) and non–ST-segment elevation myo-
cardial infarction (NSTEMI). These and other evolving
therapies led to formulation of the American College of
Cardiology/American Heart Association (ACC/AHA)
practice guidelines in 2000 (1), and a recent revision was
published in 2002 (2). As these new therapies have become
available, our challenge is to fully understand the value of
these agents, both singly and in the inevitable combinations
associated with the varied treatments and strategies used in
this diverse group of patients, and to enhance their utiliza-
tion in the medical community.
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The value of glycoprotein (GP) IIb/IIIa inhibitors in
patients with acute coronary syndromes (ACS) who un-
dergo percutaneous coronary interventions (PCIs) is well
established. In a pooled analysis of the GP IIb/IIIa inhib-
itors in PCI trials, a statistically significant 33% relative risk
reduction in the composite end points of death, non-fatal
myocardial infarction (MI), and urgent revascularization at
30 days was reported, favoring the use of these agents versus
placebo (7.8% vs. 11.6%) (3). This benefit was almost
entirely achieved within the first 48 h and persisted for at
least one year. Although there were significant increases in
minor bleeding (3), there were no increases in major
bleeding. The most recent revisions of the ACC/AHA
guidelines consider the use of these agents in patients with
UA/NSTEMI undergoing PCI a Class I indication (2).
The use of GP IIb/IIIa inhibitors in patients with
UA/NSTEMI not routinely scheduled to undergo early
coronary revascularization has also been studied, but in a less
uniform manner and with less consistent results. A meta-
analysis of the six major randomized clinical trials conducted
between 1994 and 2000 addressing this issue involving
31,402 patients in 41 countries was recently reported (4).
Clinical trials were included if the patients presented with
an ACS without persistent ST-segment elevation, if a GP
IIb/IIIa inhibitor was compared with placebo or control
therapy, and if avoidance of early (48 h) coronary revas-
cularization was recommended. A variety of GP IIb/IIIa
inhibitors was used in these trials (tirofiban, lamifiban,
eptifibatide, and abciximab) for a variable duration of
therapy, and the protocol recommendations concerning
invasive management were also quite variable. In some
studies revascularization was discouraged for at least 48 h; in
others it was encouraged after 48 h if indicated by angiog-
raphy; and in others it was at the discretion of the treating
physician. Revascularization procedures were performed in
these studies in approximately 18% of patients by five days
after randomization and in 38% by 30 days (no significant
difference in revascularization between those treated with
GP IIb/IIIa inhibitors and those not). The specific indica-
tions for revascularization in those patients who underwent
revascularization are not provided. The meta-analysis found
a 16% relative risk reduction of the odds of death or MI at
five days with the use of GP IIb/IIIa inhibitors compared
with placebo (5.7% vs. 6.9%, p  0.0003) and a 9%
reduction in these odds at 30 days (10.8% vs. 11.8%, p 
0.015). The absolute treatment benefit was largest in the
subset of patients with positive troponins (0.1 g/l), in
whom a 15% reduction in the odds of death or MI was
noted compared with control (10.3% vs. 12.0%), whereas no
risk reduction was seen in patients with negative troponins.
The treatment effect seemed larger in patients with ST-
segment depression than in those without, but the difference
did not reach significance. The benefit of GP IIb/IIIa
inhibitors was consistent in men, but women exhibited a
worse outcome than men when treated with GP IIb/IIIa
inhibitors, a difference that appeared to resolve after adjust-
ment for differences in baseline troponin values. Death or
MI at 30 days was reduced by GP IIb/IIIa inhibitors in the
group undergoing PCI or coronary artery bypass surgery
(odds ratio 0.89, 95% confidence interval [CI] 0.80 to 0.98)
but not in the patients who did not undergo revasculariza-
tion (odds ratio 0.95, 95% CI 0.86 to 1.05). Concerning
safety, GP IIb/IIIa inhibitors were associated with increased
risk of major bleeding complications (p  0.0001), which
was not dependent on concomitant treatment with heparin.
Intracranial hemorrhage was rare and was not related to GP
IIb/IIIa inhibitor use. Clearly the heterogeneity of patient
characteristics in the different trials (unstable angina vs.
non–ST-elevation MI), different agents used with different
regimens, and the vague and variable indications and timing
for revascularization make it difficult to extract definitive
conclusions concerning the value of GP IIb/IIIa inhibitors
in patients who are managed with an early conservative
strategy.
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The only randomized trial to specifically address the value
of routine GP IIb/IIIa inhibitor therapy for high-risk
patients with ACS who were treated with an early conser-
vative strategy was the GUSTO IV-ACS trial, reported in
2001, which enrolled 7,800 patients with chest pain and
either ST-segment depression or elevated troponin concen-
trations (5). Patients were treated with abciximab bolus and
24-h infusion, abciximab bolus and 48-h infusion, or
placebo in addition to aspirin and either unfractionated
heparin or dalteparin, a low molecular weight heparin.
Surprisingly, there was no significant treatment effect with
abciximab on the development of death or MI up to 30 days
(8.0% of placebo patients, 8.2% of patients with the 24-h
infusion, and 9.1% of patients with the 48-h infusion). In
fact, the mortality at 48 h was lower in the placebo-treated
patients than in the abciximab-treated patients (0.3%, 0.7%,
and 0.9%, respectively, p  0.008). Abciximab was associ-
ated with significantly increased minor bleeding in both
dosage regimens and increased major bleeding in the 48-h
infusion regimen (p  0.05), excluding bleeding associated
with cardiac surgery.
The initial ACC/AHA guidelines in September 2000
recommended GP IIb/IIIa therapy in all patients with
positive cardiac markers (Class I) (1); however, on the basis
of these emerging data over the past two years, the most
recent revised ACC/AHA guidelines have given a Class IIa
recommendation to the use of eptifibatide or tirofiban in
patients with continuing ischemia, an elevated troponin, or
with other high-risk features in whom an invasive therapy is
not planned. A Class III recommendation is given to the use
of abciximab in this setting.
In the current issue of the Journal, Peterson et al. (6)
report the patient and hospital characteristics and subse-
quent outcomes for 60,770 patients with NSTEMI treated
between July 2000 and July 2001 at 1,189 hospitals in the
U.S. according to whether they received GP IIb/IIIa inhib-
itors within 24 h of admission, as suggested by the ACC/
AHA 2000 guidelines. This enormous observational study
was based on data from the National Registry of Myocardial
Infarction 4 (NRMI 4). Their goal was to determine
whether these new agents were being used in community
practice nationwide in a manner recommended by the
guidelines and to determine their safety and efficacy in this
broad range of hospitals. They employed extensive and
multiple adjustment and analytical techniques to avoid
potential causes of treatment selection bias. In an effort to
determine the value of early GP IIb/IIIa inhibitor therapy in
conservative medical management, they repeated the anal-
yses after excluding those who received PCI within the first
24 h, after excluding all PCI patients, and after excluding all
patients who underwent cardiac catheterization.
Their results are impressive and quite compelling for a
number of reasons. Perhaps most important—and disturb-
ing—is the remarkably low use of these powerful and
effective agents in the community. They observed that
despite the published guidelines, only 25% of eligible
patients were in fact treated with these agents. It is possible
that some explanation for the lack of use of these agents is
that some physicians may not have been convinced at the
time that the use of GP IIb/IIIa inhibitors was justified for
patients with NSTEMI unless they were to undergo cardiac
catheterization and PCI. The knowledge base for appropri-
ate use of GP IIb/IIIa inhibitors was clearly evolving during
this period, as evidenced by the GUSTO IV-ACS study, as
previously noted. If patients were treated in a community
hospital or by non-cardiologists, then the lack of appropri-
ate use of these agents may also be due to unfamiliarity with
the use and indications of these therapies. Lack of use by
cardiologists may reflect the perception that GP IIb/IIIa
inhibitors should generally be reserved as a last resort
medical therapy in cases where patients continue to have
symptoms despite treatment with conventional approaches
such as heparin, nitrates, calcium-channel blockers, and
beta-blockers.
It is particularly disturbing that only 9% of the high-risk
patients received GP IIb/IIIa inhibitor therapy, compared
with 45% of low-risk patients with NSTEMI. What could
have led to such a paradoxical use of GP IIb/IIIa inhibitors?
One reason might be the selection bias of this observational
study. It may be that more of the high-risk patients were
referred for cardiac catheterization and that GP IIb/IIIa
inhibitors were started during/after PCI after 24 h. These
patients would have all been classified under the “no
therapy” group by Peterson et al. (6). Physicians in the
community may also not have considered all of the osten-
sibly “eligible” patients to be sufficiently high-risk to warrant
these potentially high-risk medications. Although these
patients had positive cardiac markers, 25% presented with
ST-segment depression, and among the patients not treated
with GP IIb/IIIa inhibitors, barely 50% presented with
chest pain (7).
Another striking observation from this large-scale study
is that those patients who were treated with GP IIb/IIIa
inhibitors consistently experienced an improved outcome
compared with those not so treated, an effect that persisted
despite all adjustments. The overall unadjusted mortality
rate (3.3% vs. 9.6%, p 0.001) and the rates of death or MI
(4.5% vs. 10.3%, p  0.001) both favored the group treated
with early GP IIb/IIIa inhibitors. The greatest absolute
benefit was observed in patients with high-risk features on
presentation, but even low-risk patients fared better with
early use of these agents, by contrast with results from the
previous meta-analysis (4). Patients appeared to benefit if
they were managed with either an initial invasive or con-
servative strategy. In regard to safety, patients receiving GP
IIb/IIIa inhibitors had a slight but significantly increased
risk of major bleeding compared with controls (10% vs.
9.5%, p  0.04) but had a similarly low risk of intracranial
hemorrhage (0.1%).
Although the results of the Peterson study strongly favor
early GP IIb/IIIa inhibitor therapy for all NSTEMI pa-
tients, the observational nature of this study cannot be
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overestimated. There are important features that suggest
that not all of the benefit in the patients who received GP
IIb/IIIa inhibitor therapy was a result of administration of
the drug alone. Those hospitals that had the highest use of
early GP IIb/IIIa inhibitor treatment (treatment of 30% to
85% of eligible patients) had nearly 50% lower mortality
rates than the centers with the least use. Those patients
treated early with GP IIb/IIIa inhibitors were more likely to
be treated by a cardiology consultant, to be treated with
optimal routine medications such as aspirin and beta-
blockers, and to undergo in-hospital catheterization and
PCI. Those hospitals in which early GP IIb/IIIa therapy
was administered were larger, more frequently offered an-
gioplasty and bypass surgery facilities, and were teaching
hospitals. Early treatment with GP IIb/IIIa inhibitor agents
appears to be a surrogate for better care by cardiologists in
a more experienced treatment facility.
Despite these caveats, the results remain impressive. The
main message of the study (i.e., that patients with NSTEMI
have been undertreated) cannot be overemphasized. This
message underscores the urgent need for campaigns within
the medical community, such as the AHA’s “Get With the
Guidelines” program, to enhance dissemination of impor-
tant therapeutic advances to the medical community and
thereby improve patient outcomes.
The results from the Peterson study, however, cannot be
construed at this time to indicate that all patients with
NSTEMI should now be treated early with GP IIb/IIIa
inhibitors. Certainly for those patients with NSTEMI who
are intended to undergo coronary angiography and PCI,
early treatment with GP IIb/IIIa inhibitors is clearly indi-
cated. The group that remains most problematic at this
time, however, consists of those patients who appear to be at
low risk and who can be managed with an initial conserva-
tive medical approach. As the experience from GUSTO
IV-ACS illustrates, a focused randomized clinical trial may
not support the results of meta-analyses or subgroup anal-
yses from other trials. It will be important to pursue
randomized clinical trials with GP IIb/IIIa inhibitors other
than abciximab, particularly in lower risk patients, to deter-
mine if these agents have a role in primary medical man-
agement.
The issue of concomitant medications will also need to be
addressed carefully with appropriate clinical investigations
before GP IIb/IIIa inhibitors are given to all NSTEMI
patients, including those at low risk. The risks and benefits
of newer combinations of anticoagulant and antiplatelet
therapies will need to be assessed in the setting of GP
IIb/IIIa inhibitor use in ACS patients, including low
molecular weight heparins, direct thrombin inhibitors, clo-
pidogrel, and tissue factor inhibitors.
This important study by Peterson et al. serves to illustrate
both how valuable new forms of therapy may be, with the
caveat of the observational nature of the study, and how
unacceptably slow the medical community can be to incor-
porate such therapies into routine care. For patients with
NSTEMI who are undergoing PCI, the floodgates are wide
open for routine GP IIb/IIIa inhibitor use. For lower-risk
patients who are to be treated with a conservative strategy,
more randomized trials are necessary before their wide-
spread use can be uniformly recommended.
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